(Q33269898)

24 July 2017

title

Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine (English)

1 reference

24 July 2017

0 references

Little SF

1

1 reference

24 July 2017

Ivins BE

2

1 reference

24 July 2017

Webster WM

3

1 reference

24 July 2017

Norris SL

4

1 reference

24 July 2017

Andrews GP

5

1 reference

24 July 2017

language of work or name

English

0 references

publication date

2 January 2007

1 reference

24 July 2017

number of pages

7

1 reference

inferred from page(s)

published in

Vaccine

1 reference

24 July 2017

volume

25

1 reference

24 July 2017

issue

15

1 reference

24 July 2017

page(s)

2771-2777

1 reference

Molecular basis for improved anthrax vaccines

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Analysis of adverse events after anthrax immunization in US Army medical personnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, US Armed Forces, 1998-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Adverse medical events in British service personnel following anthrax vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Search for correlates of protective immunity conferred by anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Production in vitro of the toxin of Bacillus anthracis previously recognized in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

In vitro correlate of immunity in a rabbit model of inhalational anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Anthrax: the disease in relation to vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Development of an in vitro-based potency assay for anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Pluronic F127-based systemic vaccine delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Anthrax capsule vaccine protects against experimental infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

N-fragment of edema factor as a candidate antigen for immunization against anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

7 January 2021

inferred from DOI database lookup

Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

7 January 2021

inferred from DOI database lookup

Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.043

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.VACCINE.2006.12.043

1 reference

24 July 2017

1 reference